Aarhus, Denmark
Aarhus, Denmark

Time filter

Source Type

Byla P.,University of Aarhus | Byla P.,Borean Pharma | Andersen M.H.,Borean Pharma | Holtet T.L.,Borean Pharma | And 7 more authors.
Journal of Biological Chemistry | Year: 2010

Inhibition of tumor necrosis factor α (TNFα) is a favorable way of treating several important diseases such as rheumatoid arthritis, Crohn disease, and psoriasis. Therefore, an extensive range of TNFα inhibitory proteins, most of them based upon an antibody scaffold, has been developed and used with variable success as therapeutics. We have developed a novel technology platform using C-type lectins as a vehicle for the creation of novel trimeric therapeutic proteins with increased avidity and unique properties as compared with current protein therapeutics. We chose human TNFα as a test target to validate this new technology because of the extensive experience available with protein-based TNFα antagonists. Here, we present a novel and highly specific TNFα antagonist developed using this technology. Furthermore, we have solved the three-dimensional structure of the antagonist-TNFα complex by x-ray crystallography, and this structure is presented here. The structure has given us a unique insight into how the selection procedure works at a molecular level. Surprisingly little change is observed in the C-type lectin-like domain structure outside of the randomized regions, whereas a substantial change is observed within the randomized loops. Thus, the overall integrity of the C-type lectin-like domain is maintained, whereas specificity and binding affinity are changed by the introduction of a number of specific contacts with TNFα. © 2010 by The American Society for Biochemistry and Molecular Biology, Inc.


Loading Borean Pharma collaborators
Loading Borean Pharma collaborators